I have an active basic and clinical research program. I have been principal investigator on several funded clinical studies including investigations of an oral ganciclovir prodrug to treat CMV retinitis and a study to determine the safety of a cyclosporine sustained drug delivery implant in the treatment of uveitis. I am principal investigator of an ongoing multicenter trial of a fluocinolone sustained drug delivery implant to treat patients with severe uveitis and a trial of this same implant to treat diabetic macular edema. Recently, I have investigated the use of ultrasonography and optical coherence tomography to diagnose macular edema in a variety of ocular diseases. I have maintained an ongoing basic research program to test the hypothesis that cytokines are important in the development of proliferative vitreoretinopathy, an important intraocular wound healing disorder. Education: I am actively involved in resident and fellow education. I give lectures to residents and fellows on a variety of topics related to uveitis and vitreoretinal diseases and train fellows to perform vitreoretinal surgery. I train post-doctoral students and medical students to conduct clinically relevant research. I serve as a mentor for the Duke third year medical school research program. I have served on a yearly basis as course faculty at many national and international meetings.
Education and Training
- University of California San Francisco, School of Medicine, M.D. 1983
Selected Grants and Awards
- Novartis DRC An open-label first-in-human single ascending dose study to explore the safety, tolerability and efficacy of subretinal administration of CPK850 gene therapy in patients with retinitis pigmentosa caused by mutations in the RLBP1 gene
- Brolucizumab Switch and Extend Ph IIIb Study: A Canadian, multi-center, single-arm, open label study assessing the efficacy and safety of brolucizumab 6mg in a Treat and Extend regimen in patients with nAMD with prior anti-VEGF exposure (PEREGRINE)
- Gemini DRC A Prospective Natural History Study to Evaluate Clinical Characteristics and Disease Progression in Subjects with Non-central Geographic Atrophy (GA) Who Are Carriers of High-risk Genetic Variants of Complement Factor H (CFH)
- Gemini DRC NH01 Genetic Screening and Registry Study to Evaluate Long-term Clinical Outcomes and Disease Progression in Subjects with Non-central GA Who Are Carriers of High-risk Genetic Complement Variants Associated with Dry AMD
- Rate of Progression in EYS-Related Retinal Degeneration (PRO-EYS)
- Rate of Progression in USH2A Related Retinal Degeneration (RUSH2A)
- A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- A Multi-Center, Randomized, Double-masked, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-related Macular Degeneration (nAMD)
- A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA
- A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to AMD
- Genentech DRC A MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED, ACTIVE-COMPARATOR STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINOPATHY WITH OR WITHOUT DME
- Diabetic Retinopathy Clinical Research Network (DRCR.net)
- ROCHE DRC PH 1 STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF RO7250284 FOLLOWING ITV ADMINISTRATION OF UNMASKED MULTIPLE ASCENDING DOSES AND MASKED SUSTAINED DELIVERY FROM THE PORT DELIVERY SYSTEM IN PATIENTS WITH NAMD
- Ripple DRC Ph 2 Evaluation of Safety and Efficacy of IBE-814 IVT Implant - A Sustained, Low Dose Dexamethasone Therapy for the Treatment of Patients with Diabetic Macular Edema (DMO) and Macular Edema due to Retinal Vein Occlusion (RVO).
- Genentech-A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF THE RANIBIZUMAB PORT DELIVERY SYSTEM IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WHO HAVE COMPLETED A GENENTECH SPONSORED STUDY
- Genentech DRC A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION
- GENENTECH DRC A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION
- Hemera DRC A Phase 2 Multi-Center Trial Evaluating Intravitreal AAVCAGsCD59 Compared to Sham Injection for the Treatment of Advanced Dry Age-Related Macular Degeneration with Geographic Atrophy
- A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea, administered intravitreally, in patients with neovascular age-related macular degeneration.
- IVERIC DRC PH 3 MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF INTRAVITREAL ADMINISTRATION OF ZIMURA¿ (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO DRY AMD
- Novartis DRC Basic human research study of novel glaucoma endpoints and identification of optimal patient populations for neuroprotection trials
- IONIS DRC A Phase 2, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to AMD
- LMRI DRC Phase 3 Clinical Trial of CNTF for MacTel Type 2-NTMT-03
- Genentech -A PHASE III RANDOMIZED, VISUAL ASSESSOR MASKED, ACTIVE COMPARATOR, MULTICENTER EVALUATION OF THE EFFICACY, SAFETY AND PHARMACOKINETICS OF THE RANIBIZUMAB PORT DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF RANIBIZUMAB IN PATIENTS WITH nAMD
- Novartis DRC A one-year, single-arm, open-label, multicenter study assessing the effect of brolucizumab on disease control in adult patients with suboptimal anatomically controlled neovascular age-related macular degeneration (SWIFT)
- GEMINI DRC Ph1, Multicenter, Open-label, Single-dose, Dose-escalation Study in Patients with Geographic Atrophy (GA) Secondary to Dry AMD to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Intravitreal Injections of GEM103
- A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE
COMPARATOR¿CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
(LUCERNE) - A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE
COMPARATOR¿CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
(TENAYA) - A Phase 1b, Prospective, Multicenter, Randomized, Single Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema (DME)
- Thrombogenics DRC - A Phase 1, open-label, multicenter, dose escalation study to evaluate the safety and tolerability of a single intravitreal injection of THR-149 for the treatment of diabetic macular edema (DME)
- Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy
- Roche DRC Multi-center, non-randomized, open-label, multiple ascending dose study to investigate the safety, tolerability,pharmacokinetics, and pharmacodynamics of RO7200394 following intravitreal administration in patients with nAMD
- Thrombogenics DRC A Phase 1, open-label, multicenter, dose escalation study to evaluate the safety and tolerability of a single intravitreal injection of THR-687 for the treatment of diabetic macular edema (DME)
- Lumithera DRC A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation (PBM) in Subjects with Dry Age-Related Macular Degeneration (AMD)
(LIGHTSITE III) - Evaluation of the Heidelberg Engineering SPECTRALIS with Flex Module for In-vivo Imaging in the Supine Position
- Kato DRC Safety and Treatment Benefit of RESOLV ER¿ in Subjects with Mild to Moderate Non-Proliferative Diabetic Retinopathy
- A 48 Week Phase II, Randomized, Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Two (2) EYS606 (pEYS606 administered by injection and electrotransfer to the ciliary muscle) Treatment Regimens in Patients with CNIU
- SCD DRC A Phase 3 Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity between SCD411 and Eylea® in Subjects with Neovascular Age-related Macular Degeneration
- Santen DRC AVANTE Study (Phase II) - Assess Efficacy, Safety of Intravitreal Injections of DE-122 in combination with Lucentis® Compared to Lucentis® Monotherapy in Subjects with Wet AMD
- LMRI DRC MacTel Phase II
- Regeneron DRC A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
- Gemini DRC A Multicenter, Open-label, Multiple Dose Study in Patients with Geographic Atrophy Secondary to Dry AMD to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103
- A PHASE IIIb OPEN-LABEL, SINGLE-ARM STUDY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TO EVALUATE THE USABILITY OF RANIBIZUMAB 10 mg/0.1 mL PREFILLED SYRINGE WITH THE PORT DELIVERY SYSTEM
- Novartis DRC HAWK Centralized Imaging and Adjudication services, RTH258A/C1001502/I150 RTH258A2301
- Novartis DRC A 96-week, two-arm, randomized, single-masked, multi-center, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy
- Senju DRC A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of MT-0814 for the Treatment of Patients with Age-Related Macular Degeneration
- QLT DRC RET IRD 04: A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)
- Astellas DRC Phase 1b, Dose Escalation Evaluation of Safety and Tolerability and a Ph 2, Randomized, Parallel Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to AMD
- A Phase I/II, open-label, multicentre, dose escalation study assessing the safety and tolerability of pEYS606 when administered by electrotransfer (ET) in the ciliary muscle of patients with non infectious posterior, intermediate or panuveitis.
- ONL DRC A Phase 1 Open-Label, Dose Escalation Study to Assess the Safety and Tolerability of Intravitreal ONL1204 in Patients with Macula-off, Rhegmatogenous Retinal Detachment
- Regenxbio DRC A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy with RGX-314 in Subjects with Neovascular AMD (nAMD)
- UPENN - Additional Analysis of Data from the Comparison of Age-related Macular Degeneration Treatments Trials CATT and CATT Follow-up Study (CATT FS)
- Mallinckrodt DRC A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Severe Noninfectious Intermediate,
Posterior, or Panuveitis - Novartis DRC A multicenter, randomized, double-masked Phase 3a study to assess safety and efficacy of brolucizumab 6mg dosed Q4 weeks compared to Q8 weeks in high anti-VEGF-need patients with neovascular age-related macular degeneration (nAMD)
- Allgenesis DRC A Multicenter, Prospective, Randomized, Double-masked Study Evaluating the Safety, Tolerability, and Efficacy of Topical AG-86893 in Patients with Pterygium
- Genentech DRC A PHASE III, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINOPATHY (PAVILION)
- A PHASE 2/3 RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTIONS TO SUBJECTS WITH ACUTE NON ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY (NAION)
- Evaluation of retinal cavitations in macular telangiectasia type 2 and response to ciliary neutrophic factor (CNTF)
- DRC Editas Natural History Study of CEP290-Related Retinal Degeneration
- An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated with a Flucinolone Acetonide Intravitreal Implant
- AN OBSERVATIONAL BILATERAL EVALUATION OF CORNEAL ENDOTHELIAL CELL DENSITY IN SUBJECTS WHO HAVE HAD A FLUOCINOLONE ACETONIDE IMPLANT FOR AT LEAST ONE YEAR
- A PHASE Ib STUDY EVALUATING COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH ADVANCED BRAFV600 WILD-TYPE MELANOMA WHO HAVE PROGRESSED DURING OR AFTER TREATMENT WITH ANTI¿PD-1 THERAPY
- Macular Edema Treatment Trials Associated with MUST (META-MUST)
- A Multi-Center, Open-Label, Parallel-Arm, Randomized, Dose-Ranging Study of ENV515 (travoprost) Intracameral
Implant in Subjects with Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma - A CONTROLLED, MULTI-CENTER STUDY OF THE UTILIZATION AND SAFETY OF THE MK II INSERTER AND THE SAFETY OF THE FAI INSERT IN SUBJECTS WITH NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
- A RANDOMIZED, CONTROLLED, DOUBLE-MASKED, CROSSOVER CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND EXPLORATORY EFFICACY OF 1.0 mg LUMINATE® (ALG-1001) AS A TREATMENT FOR NON-EXUDATIVE MACULAR DEGENERATION
- Ophthotech DRC Phase 2 OPH2007 - A Phase 2A Open-Label Trial to ASSESS the Safety of Zimura¿ (anti-c5) Administered in Combination With Lucentis® 0.5 mg in Treatment naive subjecTs with Neovascular Age related macular degeneration
- pSivida PSV-FAI-001 Duke as Site
- SciFluor DRC Wet AMD study
- A prospective, single-center, randomized, double masked, sham controlled study to evaluate the safety, efficacy and tolerability of OTX-TI (sustained release travoprost) Intracameral Depot compared to topical travoprost in subjects with OA & OHT.
- PRN/Stealth DRC An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects with Intermediate Age-Related Macular Degeneration
- Computer Aided Classification of Diabetic Macular Edema
- A Randomized, Double Masked, Active Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration
- A Randomized, Double Masked, Active Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Diabetic Macular Edema
- Acucela DRC A Phase 2a Multicenter, Randomized, Masked Study Evaluating the Pharmacodynamics of Emixustat
Hydrochloride in Subjects with Macular Atrophy Secondary to Stargardt Disease - A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies
- ThromboGenics DRC OASIS study - provide raw images
- A Phase 1b/2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to
Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936559
in Subjects with Severe Sepsis - UPenn - NEI Follow-up Study: Comparison of AMD Treatment Trials (CATT) YR3
- Neurotech DRC NT-503 (GEN 3)
- Evaluate Systemic Immunosuppression Regimens as Graft Rejection Prophylaxis Following Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial Cells in Patients with Geographic Atrophy Secondary to AMD
- Competitive Renewal for Multicenter Uveitis Steroid Treatment (MUST) Trial
- A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects with Behcet's Disease Uveitis
- River Vision DRC DME
- Alcon DRC OVID II RTH255-P001
- A 12-month study to investigate the efficacy, safety and pharmacokinetics of a monthly dosing regimen of ranibizumab (0.5 mg) in combination with pegpleranib (1.5mg), compared to monthly raranibizumab (0.5 mg)
monotherapy, in patients with nAMD - A 12-month, multi-center, open-label study to investigate the safety of pegpleranib (1.5 mg) in combination with anti-VEGF agents, ranibizumab (0.5 mg) or aflibercept (2 mg), in Japanese patients with neovascular age-related macular degeneration
- Coordinating Center for the Comparison of AMD Treatments Trials
- Comparison of AMD Treatment Trials-OCT Reading Center
- CATT OCT Reading Center
- Cytokine Modulation in Proliferative Vitreoretinopathy
- Cytokine Modulation In Proleferative Vitreoretinopathy
- Cytokine Modulation In Proliferative Vitreoretinopathy
- Cytokine Modulation In Proliferative Vtreoretinopathy
- Modulation Of Na+K+ Atpase In Retinal Detachment